Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Parecoxib, Oporia Setbacks Reflect Tougher FDA Stance, CEO Says

Executive Summary

Pfizer's research & development productivity has been impacted by a more difficult, risk-averse regulatory environment at FDA, CEO Hank McKinnell said during an earnings call Oct. 20

You may also be interested in...



Pfizer Cost-Cutting: Details Are Sketchy, But Sales Force Is On The Table

Pfizer CEO Jeffrey Kindler has opened the door to sales force reductions as part of the firm's latest cost-cutting initiative, announced Oct. 1

Pfizer Cost-Cutting: Details Are Sketchy, But Sales Force Is On The Table

Pfizer CEO Jeffrey Kindler has opened the door to sales force reductions as part of the firm's latest cost-cutting initiative, announced Oct. 1

Pharma Investors Need To Look Long Term, Especially With Pfizer – McKinnell

Pharmaceutical industry investors should be less concerned about short-term performance in a sector with an extended business cycle, Pfizer CEO Hank McKinnell said June 13

Related Content

Topics

UsernamePublicRestriction

Register

PS046472

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel